Skip to main content

Advertisement

Table 4 LDR versus HDR for overall mortality, local recurrence and late complications

From: Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy – a meta-analysis of clinical trials

Overall mortality
Stage Number of studies Total patients Patients/events HDR Patients/events LDR OR CI95% P value
I 2 134 19/67 13/67 0.68 0.36–1.29 0.23
II 4 500 75/257 62/243 0.84 0.56–1.24 0.38
III 5 1079 238/572 228/507 1.22 0.95–1.56 0.11
Local recurrence
Stage Number of studies Total patients Patients/events HDR Patients/events LDR OR CI95% P value
I 2 134 7/67 3/67 2.31 0.61–8.71 0.22
II 4 500 45/257 34/243 1.17 0.74–1.85 0.51
III 5 1079 143/572 138/507 0.94 0.70–1.27 0.70
Grade 3 or 4 rectal complication
  Number of studies Total patients Patients/events HDR Patients/events LDR OR CI95% P value
  5 2065 27/1068 27/997 0.9 0.52–1.56 0.7
Grade 3 or 4 bladder complication
  Number of studies Total patients Patients/events HDR Patients/events LDR OR CI95% P value
  5 2065 17/1068 16/997 0.98 0.49–1.96 0.95
Grade 3 or 4 small intestine complication
  Number of studies Total patients Patients/events HDR Patients/events LDR OR CI95% P value
  3 783 13/432 3/351 3.15 0.9–10.37 0.06